丙哌卡因 | 3670-68-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 丙哌卡因
• 中文别名: 普匹卡因；丙达克罗宁
• 英文名称: falicain
• 英文别名: propipocaine；4'-propoxy-3-piperidinopropiophenone；3-piperidin-1-yl-1-(4-propoxyphenyl)propan-1-one
• CAS: 3670-68-6
• 化学式: C₁₇H₂₅NO₂
• mdl: MFCD00699374
• 分子量: 275.391
• InChiKey: STHAHFPLLHRRRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  丙哌卡因 在 aluminum isopropoxide 、 异丙醇 作用下， 生成 1-(4-propoxy-ξ-cinnamyl)-piperidine
  参考文献：
  名称：

  Profft et al., Journal fur praktische Chemie (Leipzig 1954), 1954, vol. <4> 1, p. 57,75

  摘要：

  DOI：
• 作为产物：
  描述：

  3-chloro-1-(4-propoxy-phenyl)-propan-1-one 在 甲醇 、 potassium acetate 作用下， 生成 丙哌卡因
  参考文献：
  名称：

  Profft et al., Journal fur praktische Chemie (Leipzig 1954), 1954, vol. <4> 1, p. 57,75

  摘要：

  DOI：

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Crosslinked hyaluronic acid compositions for tissue augmentation
  申请人：Sadozai K. Khalid

  公开号：US20050136122A1

  公开（公告）日：2005-06-23

  A hyaluronic acid (HA) composition includes crosslinked, water-insoluble, hydrated HA gel particles. The HA includes crosslinks represented by the following structural formula: HA—U—R 2 —U—HA The variables are defined herein. A method of augmenting tissue in a subject includes inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with the HA composition, and applying force to the syringe, to deliver the HA composition into the subject. A method of preparing the HA composition, includes forming water-insoluble, dehydrated crosslinked HA particles, separating the water-insoluble, dehydrated particles by average diameter, selecting a subset of particles by average diameter, and hydrating the subset of dehydrated particles with a physiologically compatible aqueous solution. Another method of preparing the crosslinked HA composition includes crosslinking a precursor of the crosslinked HA with a biscarbodiimide in the presence of a pH buffer and dehydrating the crosslinked HA. Also included is a method of augmenting tissue in a subject that is in need of tissue augmentation. A method of stabilizing crosslinked HA includes hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G′ for the stabilized composition is at least about 110% of the value of G′ for a non-stabilized composition,. Also included is the stabilized HA composition.

  一种透明质酸（HA）组合物包括交联的、不溶于水的、水合的HA凝胶颗粒。HA包括由以下结构式表示的交联：HA—U—R2—U—HA。变量在此定义。一种在受试者中增强组织的方法包括将针插入受试者体内需要组织增强的位置，其中针连接到装有HA组合物的注射器，并施加力量到注射器，将HA组合物注入受试者体内。一种制备HA组合物的方法包括形成不溶于水的、脱水的交联HA颗粒，通过平均直径分离不溶于水的、脱水的颗粒，通过平均直径选择颗粒的子集，并用生理兼容的水溶液使脱水的颗粒子集水化。另一种制备交联HA组合物的方法包括在pH缓冲剂存在下用双异氰酸酯交联交联HA的前体，并脱水交联HA。还包括一种在需要组织增强的受试者中增强组织的方法。一种稳定交联HA的方法包括用含有局部麻醉剂的生理兼容水溶液水化不溶于水的、脱水的交联HA，其中稳定组合物的存储模量G′的值至少为非稳定组合物G′值的约110%。还包括稳定的HA组合物。
• Metal-free synthesis of β-aminoketones by the reductive hydroamination of ynones
  作者：Rui Fu、Yu Liu、Tao Wu、Xinyu Zhang、Yang Zhu、Jiangbin Luo、Zhengyu Zhang、Yaojia Jiang

  DOI：10.1039/d2cc00169a

  日期：——

  This study describes a cascade method for the synthesis of β-aminoketones through the reductive hydroamination of alkynes under very mild metal-free conditions. It allows for the rapid conversion of ynones and amines into corresponding β-aminoketones with a broad substrate scope and diverse functionalities. This straightforward and easy-to-handle reaction process can be successfully applied for the

  本研究描述了一种在非常温和的无金属条件下通过炔烃的还原加氢胺化合成 β-氨基酮的级联方法。它允许炔酮和胺快速转化为相应的β-氨基酮，具有广泛的底物范围和多种功能。这种简单易行的反应过程可成功应用于普罗克生和普罗哌卡因的合成，为合成具有β-氨基酮骨架的药物分子提供了潜在的选择。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• [EN] NANOPARTICLES FOR NERVE PENETRATION AND USES THEREOF<br/>[FR] NANOPARTICULES DESTINÉES À PÉNÉTRER DANS UN NERF ET LEURS UTILISATIONS
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2019113184A1

  公开（公告）日：2019-06-13

  Provided herein are compositions comprising drugs (e.g., nerve blockers or nerve growth factors) encapsulated in nanoparticles (e.g., nanoparticles having a diameter of less than 70 nm). The nanoparticles described herein can penetrate the nerve and deliver the drugs into the nerve. Methods of blocking a nerve signal and/or inducing local anesthesia, and methods of promoting neuroregeneration are also provided.

  本文提供了一些由药物（例如神经阻滞剂或神经生长因子）封装在纳米粒子（例如直径小于70纳米的纳米粒子）中的组合物。本文所描述的纳米粒子可以穿透神经并将药物输送到神经中。还提供了阻断神经信号和/或诱导局部麻醉的方法，以及促进神经再生的方法。